Peptide nucleic acids (PNAs) are nucleic acid analogues in which the sugar-phosphate backbone has been replaced by a synthetic peptide backbone, usually comprised of N-(2-aminoethyl)-glycan units. PNAs targeted against mRNA can inhibit translation both in vitro and in human cells. Pyrimidine rich PNAs can physically block translation elongation at targets in the coding region of messenger RNA, giving rise to a truncated protein. Truncated proteins that lack a functional domain and can at the same time inhibit the function of the wild type protein are referred to as dominant negative. Truncated form of Insulin-like Growth Factor-1 receptor (IGF1R), protein overexpressed in numerous cancers, inhibits tumorigenesis and resistance to apoptosis of cancerous cells. One of the biggest limitations to the use of PNAs in vivo is their poor internalization. It is therefore necessary to develop efficient transporters able to enhance the cellular uptake of PNAs. Cell-penetrating peptides (CPPs) are natural or synthetic peptides that can be conjugated to different molecules in order to facilitate their cellular uptake. The objectives of this thesis were to understand the conditions required for the translation elongation arrest by PNAs and to study their cellular internalization mediated by CPP (R/W)9. We have shown that covalent coupling of two 13-mer PNAs to (R/W)9 facilitates their internalization in a reporter cell line, leading to their biological activity in the presence of a lysosomotropic agent such as chloroquine. The conjugates interact with membrane glycosaminoglycans and are internalized by endocytosis in less than one hour. Moreover, conjugates formed with an analogue peptide containing lysines in the place of arginines of (R/W)9 showed to be six time less efficiently internalized, suggesting the importance of arginine residues for the interaction of the conjugate with the membrane. We have also showed that the PNA targeted to the coding region of IGF1R coupled to (R/W)9 is efficiently internalized to prostate cancer cells where it inhibits the expression of the beta chain of the receptor.
